small nuclear ribonucleoprotein polypeptide C pseudogene 11Genealiases: []
Q-omics provides the consensus-scored SNRPCP11 profile across patient tissues and cancer cell-line models. SNRPCP11 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SNRPCP11 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, SNRPCP11 RNA expression shows 10,985 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, THCA, and THYM as cancer lineages where SNRPCP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPCP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPCP11 survival associations across molecular data types. SNRPCP11 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPCP11 RNA expression–survival associations across cancer types. High SNRPCP11 expression shows unfavorable associations in MESO, COAD, SKCM, CHOL and UCEC, but favorable associations in LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SNRPCP11 RNA expression.
This table summarizes SNRPCP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPCP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPCP11 shows lower tumor expression in THCA and COAD and higher tumor expression in KIRC. The THCA box plot shows higher SNRPCP11 RNA expression in normal versus tumor tissue (log2 FC = −0.196, t-test p = .005).
This table shows molecular features associated with SNRPCP11 in patient tissues and cancer cell lines. In patient samples, SNRPCP11 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
